Dr. Winoto’s team new study, supported by IVRI and Aduro Biotech (grant #043572), demonstrates a novel approach that leads to effective T‐cell responses against tumors in mice with potential future applications in humans.
Bristol Myers Squibb invests in Dragonfly Therapeutics, a company co-founded by IVRI faculty director, David Raulet